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Mounting evidence indicates that polyfunctional T cells,
effector T cells capable of simultaneously producing multi-
ple pro-inflammatory cytokines, are more efficacious in
controlling infection and cancer. Our previous study
reported that adoptive transfer of tumor-specific CD4+ T
cells following chemotherapy gave rise to polyfunctional
CD4+ effector cells, characterized by concomitant expres-
sion of CD40L, IFNg, TNFa, IL2 and granzyme B. One
unique feature of these highly activated polyfunctional
CD4+ effector cells was the high level expression of IL7
receptor, suggesting that IL7 plays a critical role in the
generation and maintenance of these cells. In this project,
we studied how IL7 signaling confers polyfunctionality to
CD4+ T cells. We found that only IL7, but not other IL2
family cytokines can promote the acquisition of polyfunc-
tionality in naïve CD4+ T cells upon antigenic stimulation
in vitro. IL7 signaling resulted in increased histone acetyla-
tion in the promoters of effector molecules including
IFNgamma and IL2. Mechanistically, PI3K activation was
required for polyfunctionality. Administration of rIL7 fol-
lowing chemotherapy and CD4+ T cell adoptive therapy
led to enhanced and sustained presence of polyfunctional
CD4+ effector cells which mediated durable antitumor
effects in mice with advanced B cell lymphomas. Our
results provide novel insights into the mechanisms by
which IL7 drives the generation of polyfunctional CD4+
effector cells.
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